The hot TNF inhibitor market with Humira, ‘King of Indication’
Humira has made a series of movements to expand its indications to secure the 1st place.
According to the current industry concerned, as the Abbvie’s ‘Humira(Adalimumab)’ added two more indications recently, it is now approved incredibly for indications of 11 diseases.
Considering the Janssen’...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
